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Abstract
Objectives: REGULATE trial was designed to compare the efficacy and safety of benfluorex versus pioglitazone in type 2
diabetes mellitus (DM) patients.
Methods: Double-blind, parallel-group, international, randomised, non-inferiority trial. More than half of the 196
participating centres were primary care centres. Patients eligible had type 2 DM uncontrolled on sulfonylurea. 846 were
randomised. They received study treatment for 1 year. 423 patients were allocated to benfluorex (150 to 450 mg/day) and
423 were allocated to pioglitazone (30 to 45 mg/day). Primary efficacy criterion was HbA1c. Safety assessment included
blinded echocardiographic evaluation of cardiac and valvular status.
Results: At baseline, patients were 59.1610.5 years old with HbA1c 8.360.8%, and DM duration 7.166.0 years. During the study,
mean HbA1c significantly decreased in both groups (benfluorex: from 8.3060.80 to 7.7761.31 versus pioglitazone: from
8.3060.80 to 7.4561.30%). The last HbA1c value was significantly lower with pioglitazone than with benfluorex (p,0.001)
and non-inferiority of benfluorex was not confirmed (p=0.19). Among the 615 patients with assessable paired
echocardiography (310 benfluorex, 305 pioglitazone), 314 (51%) had at least one morphological valvular abnormality and
515 (84%) at least one functional valvular abnormality at baseline. Emergent morphological abnormalities occurred in 8
patients with benfluorex versus 4 with pioglitazone (OR 1.99), 95% CI (0.59 to 6.69). Emergent regurgitation (new or
increased by one grade or more) occurred more frequently with benfluorex (82 patients, 27%) than with pioglitazone (33
patients, 11%) (OR 2.97), 95% CI (1.91 to 4.63) and were mainly rated grade 1; grade 2 (mild) was detected in 2 patients with
benfluorex and 3 with pioglitazone. There was no moderate or severe regurgitation.
Conclusion: After 1 year of exposure, our results show a 2.97 fold increase in the incidence of valvular regurgitation with
benfluorex and provide evidence for the valvular toxicity of this drug.
Trial registration: www.controlled-trials.com ISRCTN 27354239.
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Introduction
Treatment of type 2 diabetes mellitus aims to combine
glycaemic control with safety to reduce events related to
microvascular and cardiovascular complications. We have pre-
viously evaluated the efficacy of benfluorex versus placebo in
achieving targets for glycaemic control. [1] Our results suggested
that benfluorex might be useful as a second-line antidiabetic drug
when metformin is not tolerated or contraindicated. In view of
concerns surrounding the cardiovascular safety of antidiabetic
treatments such as glitazones and sulfonylureas [2], these findings
prompted us to set up the REGULATE (Randomised, double-
blind study with comparison of bEnfluorex versus pioGlitazone in
combination with sULfonylurea administered orAlly for the
Treatment of type 2 diabEtes) trial to compare the efficacy and
safety of benfluorex with pioglitazone.
At the time of the design of the REGULATE study, a case report
had incriminated benfluorex in the development of fibrotic valvular
heart disease [3], followed later by similar observations of valvular
regurgitation [4].Benfluorex, like fenfluramine, is metabolised into
norfenfluramine [5],which is known to activate the serotonin 2B (5-
HT2B) receptor with subsequent fibroblast proliferation and
stimulation of glycosaminoglycan production [6].We therefore
decided to use REGULATE to address the issue of valvular safety
by performing a complete cardiac examination with echocardio-
graphy at baseline and at the end of the study with centralised blind
reading. In view of additional case reports of pulmonary hyperten-
sion [7],a case-control study [8],a pharmaco-epidemiological study
[9],as well as the preliminary results of REGULATE, the French
and European authorities decided to withdraw benfluorex from the
market 4 years after initiation of the study [10].We report here the
complete results of the REGULATE trial, which was designed to
compare the efficacy and safety of benfluorex versus pioglitazone
over 1 year in type 2 diabetic patients who were not optimally
controlled on sulfonylurea monotherapy.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Considerations
The trial designed in 2005 was conducted in accordance with
the ethical principles stated in the Declaration of Helsinki 1964,
as revised in Edinburgh, UK, October 2000. The protocol was
finally approved by each institution’s ethics committee (listing
provided in annexe) and LYON Sud Est II ethical committee (7
th
of December 2005). All subjects provided written informed
consent. The trial is registered on www.controlled-trials.com
(ISRCTN 27354239).
Study Design and Patients
This randomised, double-blind, double-dummy, parallel-
group, phase III study (196 centres in 8 countries) compared
the efficacy and safety of 1 year’s treatment with benfluorex
versus pioglitazone in patients with type 2 diabetes mellitus
stratified according to baseline glycosylated haemoglobin (HbA1c)
(#8% or .8%) and country. Treatment was allocated under the
responsibility of the CRO (S-Clinica, Brussels, Belgium) using a
non-adaptative, centralised, balanced (one to one), stratified
randomisation (interactive voice response system IVRS designed
by the sponsor) according to country and HbA1C (#8% or
.8%). Each investigator received a personal pass-word from the
IVRS system for treatment attribution. Both patients and
investigators were blinded to treatment allocation. Because of
metformin intolerance, all patients were treated by sulfonylurea
at their usual dose that was maintained throughout the study,
except in case of severe or repeated hypoglycaemia. The trial
design involved a 4-week placebo run-in, followed by a 4-month
uptitration period and an 8-month dose adaptation period; the
aim was to reach the maximal dose tolerated by the patient
according to HbA1c (target level ,6.5%) and tolerability. The
daily dosage of oral benfluorex (150 to 450 mg) and pioglitazone
(30 to 45 mg) was uptitrated according to fasting plasma glucose
(FPG) levels (target 7.8 mmol/L or lower). The dosage could be
reduced at any time according to safety (risk for hypoglycaemia).
Eligible patients were outpatients with type 2 diabetes mellitus
aged between 35 and 80 years with stable bodyweight (body mass
index [BMI] between 25 and 40 kg/m
2 inclusive, except in India
where BMI could range from 23 to 40 kg/m
2) and HbA1c between
7% and 10%. Patients had received a sulfonylurea at a stable dose
for at least 3 consecutive months prior to the selection visit (at least
50% of the maximal recommended dose). Clinical heart failure,
left ventricular (LV) ejection fraction less than 40%, or any
significant valvular heart disease on echocardiography were
exclusion criteria.
The pre-specified primary endpoint was HbA1c level. The pre-
specified secondary endpoints were low-density lipoprotein (LDL)
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safety criteria including echographic assessment of LV function
and valvular status. HbA1c was assessed at every visit (baseline, 1,
2, 4 7, 9, and 12 months) using NGSP-certified high performance
liquid chromatography (HPLC) (Biorad Variant I). HbA1c, FPG,
and standard biochemical, haematological, and lipid parameters,
high sensitivity C-reactive protein (hsCRP), and N-terminal pro-
brain natriuretic peptide (NT-proBNP) were assessed centrally.
Creatinine clearance was calculated according to the Cockcroft
formula.
Safety
Safety was assessed by spontaneously reported adverse events,
physical examination, recording of vital signs at each visit, and
laboratory tests (including NT-proBNP) at least at baseline and
final visit. A cardiac examination with 12-lead electrocardiogram
and echocardiography was performed at baseline and final visit,
and in case of suspected heart failure. Hypoglycaemic events were
recorded in a patient diary and were based on suggestive clinical
symptoms only and graded as mild, moderate, or severe. All
cardiovascular events and serious events were blindly adjudicated
by a Safety Committee during meetings on a monthly basis.
Echocardiography
All enrolled patients underwent a complete transthoracic
examination performed before entry to the study and at discharge
with the same equipment within each centre. Each echocardio-
graphy centre was accredited by the Core Laboratory prior to
Figure 1. Flow of participants.
doi:10.1371/journal.pone.0038273.g001
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morphological study of the mitral, aortic, and tricuspid valves in
addition with valvular and LV function. Recordings were
centralised (Biomedical Systems, Missouri, USA) and then
interpreted consensually by two experts (Ho ˆpital Louis Pradel,
Lyon, France) who were blinded to the treatment group but not to
echocardiography sequence. To ensure that all clinically signifi-
cant and non-significant valvular abnormalities were noted, a side-
by-side interpretation of pairs of echocardiographic recordings was
performed, including morphological (thickness, calcification) and
functional (stenosis and regurgitation) assessment. This entire
reading process was carried out over 3 months at the end of the
study, according to a pre-specified protocol, before the study
unblinding.
Abnormal valvular thickening was considered to be present
when a local or widespread thickness of more than 3 mm was
observed [11].Semi quantitative assessment of valve regurgitation
was made according to the recommendations of the American
Society of Echocardiography [12].Mitral or tricuspid valve
regurgitation was graded using the colour Doppler jet-area
method. Aortic regurgitation was graded according to the ratio
of the width of the colour jet to the diameter of the outflow tract.
Valve regurgitation was defined and quantified as follows:
absent=0, minor=1, mild=2, moderate=3, or severe=4. If
one of the two readers differed from the other by one grade, the
higher rating was assigned.
Table 1. Main demographic and baseline characteristics in the randomised set.
All (n=846) Benfluorex (n=423) Pioglitazone (n=423) p-value
Age (years) 59.1610.5 59.6610.3 58.6610.6 0.187
Male 464 (55%) 225 (53%) 239 (57%) 0.369
Ethnic origin 0.140
- Caucasian 646 (76%) 319 (75%) 327 (77%)
- Asian 157 (19%) 83 (20%) 74 (18%)
- Other 43 (5%) 21 (5%) 22 (5%)
Weight (kg) 80.5614.4 79.7614.0 81.4614.8 0.094
Body mass index (kg/m
2)2 9 . 5 64.0 29.464.0 29.764.1 0.222
Waist circumference (cm) 101.3612.1 100.6611.9 102.1612.3 0.064
Duration of diabetes (years) 7.166.0 7.466.0 6.765.9 0.098
HbA1c (%) 8.360.8 8.360.8 8.360.8 0.773
Fasting plasma glucose (mmol/L) 9.962.6 9.962.7 9.862.5 0.785
Creatinine clearance ,60 mL/min/1.73 m
2 60 (7%) 36 (9%) 24 (6%) 0.140
Values are numbers (%) or means6SD.
doi:10.1371/journal.pone.0038273.t001
Figure 2. Change in glycosylated haemoglobin (HbA1c) in the full analysis set.
doi:10.1371/journal.pone.0038273.g002
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The Scientific Committee designed and oversaw the conduct
and analysis of the trial in collaboration with representatives of the
sponsor. Data were collected, managed, and analysed by the
sponsor. The statistical analysis plan was written prior to study
unblinding. An Adjudication Committee reviewed all serious
adverse events and all cardiac and vascular adverse events, and
defined echocardiographic parameters. The manuscript was
prepared by a writing group, whose members had unrestricted
access to the data, and was subsequently revised by all authors. All
authors decided to submit the manuscript for publication and
assume responsibility for its accuracy and completeness.
Statistical Methods
Efficacy analyses were performed in the full analysis set (FAS),
which was defined as included patients who had taken at least one
dose of study treatment and who have at least one baseline and
one post-baseline evaluation of HbA1c. The safety set was defined
as included patients who had taken at least one dose of study
treatment and with post-baseline safety information.
The effect of treatment on HbA1c change from baseline to last
post-baseline value was estimated in the FAS using an analysis of
covariance (general linear model) with baseline and country (fixed
effects) as covariates. The non-inferiority of benfluorex versus
pioglitazone was studied using a non-inferiority margin set at
0.4%. The estimate (E) of the treatment difference is provided,
together with standard error (SE), two-sided 95% confidence
interval (CI), and corresponding p value. The same model was
used to provide estimates of the treatment effect for secondary
criteria. For LDL cholesterol, the superiority of benfluorex versus
pioglitazone was tested and p value provided. Post-hoc analyses
were performed to provide additional information on safety and
efficacy.
For NT-proBNP, the last post-baseline value under treatment
was compared between groups using an analysis of covariance
(general linear model) on log10-transformed value with log10-
transformed baseline and country (fixed effects) as covariates.
The rates of emergent morphological and/or functional
valvular abnormalities were compared between treatment groups
and odds ratios (ORs) and corresponding 95% CIs and p values
were provided (Wald test). The robustness of the findings was
checked using a post hoc multivariable analysis with logistic
regression adjusting for multiple covariates was performed on this
clinical event. The final model was obtained using a backward
selection method including the treatment group and the following
characteristics at baseline: age, gender, BMI, smoking habits,
diabetes duration, creatinine clearance, hsCRP, HbA1c, LDL
cholesterol, high-density lipoprotein (HDL) cholesterol, medical
history of hypertension, use of statins, and morphological and
functional valvular abnormalities.
Sample size was estimated on the change from baseline to last
value of HbA1c, to demonstrate the non-inferiority of benfluorex
versus pioglitazone, using a one-sided Student t test with a 2.5%
type I error. The study protocol initially planned that, for a 1.5%
SD and a 0.40% for the clinical equivalence margin, it was
necessary to recruit 479 subjects per group in the FAS to
demonstrate non-inferiority if the true difference was equal to zero
(60.05%), with a power of at least 95%. It was therefore planned
to include 1000 patients (500 in each group), with at least 50%
with baseline HbA1c .8%; the number was reduced to 840
included patients (800 patients in the FAS, with at least 420
included patients with HbA1c .8%) since a blinded re-estimate of
the variance of HbA1c indicated that the SD was lower (1.1%) than
expected (1.5%).
All statistical analyses were performed using SAS software
(version 8.2, SAS Institute, Cary, NC).
Results
Between March 2006 and January 2008, 847 patients were
included and 846 randomly allocated to treatment (423 ben-
fluorex, 423 pioglitazone). Follow-up ended in January 2009. The
trial profile is presented in Figure 1. The safety set (SS) comprised
844 patients and FAS 830 patients. A total of 683 patients had at
least one baseline and one post-baseline echocardiography, of
which 615 (73%) were evaluable for morphology and function on
at least one valve (310 benfluorex, 305 pioglitazone).
There were no relevant differences in demographic and baseline
characteristics between the two groups (Table 1). Overall, the
population was aged 59.1610.5 years, and had type 2 diabetes for
7.166.0 years. Patients were mildly obese (BMI, 29.564.0 kg/m
2)
with moderate blood glucose disequilibrium (HbA1c,
Table 2. Left ventricular (LV) function at baseline and at the
end of the study.
Parameter (unit) Benfluorex Pioglitazone
LV ejection fraction (%) n=204 n=196
- Baseline 69.067.2 69.167.1
- End 69.466.4 69.366.5
LV end diastolic diameter (cm) n=279 n=272
- Baseline 4.6760.64 4.7060.65
- End 4.7060.63 4.7560.63
LV end-systolic diameter (cm) n=279 n=272
- Baseline 2.7160.51 2.7560.54
- End 2.8260.57 2.8260.53
Stroke volume (mL) n=282 n=253
- Baseline 81.9644.7 82.5644.4
- End 75.7624.3 78.3624.0
Cardiac index (L/m/m
2) n=223 n=208
- Baseline 3.0360.84 2.9961.42
- End 2.7960.83 2.9060.84
Mitral E wave (cm/s) n=325 n=314
- Baseline 73.5617.1 73.6619.6
- End 72.9618.4 78.5622.0
A wave (cm/s) n=324 n=311
- Baseline 82.4620.0 82.9623.1
- End 84.4621.5 84.1622.0
Mitral E/A ratio n=316 n=309
- Baseline 0.9360.29 0.9460.33
- End 0.9060.26 0.9760.32
Mitral E wave deceleration time (s) n=310 n=290
- Baseline 238.6661.5 245.8672.2
- End 246.3674.8 236.5665.6
NTproBNP values (pg/mL) n=341 n=359
- Baseline 45.0 [26.0–95.0] 49.0 [25.0–94.0]
- End 63.0 [34.0–133.0] 70.0 [31.0–135.0]
Values are numbers (%) or means6SD, except for NT-proBNP, which are median
[Q1;Q3]). n=number of assessable patients.
doi:10.1371/journal.pone.0038273.t002
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and dyslipidaemia (357 [42%]) were frequent, though only 86
(10%) had a history of macrovascular complications and 34 (4%)
microvascular complications.
Mean treatment duration was 331697 days. Most of the
patients in the FAS were receiving maximal dose after 4 months
(313 patients (82%) with benfluorex 450 mg/day, 296 patients
(73%) with pioglitazone 45 mg/day, p=0.006). Mean HbA1c
decreased from baseline to final value in both groups (–
0.54%61.12% with benfluorex, –0.88% 61.24% with pioglita-
zone). Changes over time are presented in Figure 2. The non-
inferiority of benfluorex versus pioglitazone was not confirmed
(between-group difference 0.33, 95% CI (0.17 to 0.49), p=0.19).
The last HbA1c value was 7.8%61.3% with benfluorex and
7.5%61.3% with pioglitazone reaching a difference between
groups of 0.33%, 95% CI (0.17 to 0.49). Mean last FPG was
higher with benfluorex than with pioglitazone (8.762.8 versus
8.162.6 mmol/L, p=0.002). Last LDL cholesterol concentration
was lower with benfluorex than with pioglitazone (2.8760.79
versus 3.0360.86 mmol/L, p=0.005). Last HDL cholesterol level
was higher in pioglitazone than in benfluorex group (1.2860.33
versus 1.2560.32 mmol/L, p,0.001). At final evaluation, both
mean waist circumference and bodyweight were lower in the
benfluorex group than in the pioglitazone group (waist circumfer-
ence: 98.6611.4 versus 104.1612.6 cm, p,0.001; bodyweight:
78.2614.3 Kg versus 84.8616.0 Kg, p,0.001).The mean weight
from baseline to last value was moderately decreased in the
benfluorex group (21.663.5 kg, p,0.0001) while it increased in
the pioglitazone group (3.364.2 kg, p,0.0001).
The mean treatment duration in the patients with analyzable
echocardiograms was 346679 days and was similar in the two
groups. The mean time between baseline and final echocardio-
gram was 352674 days. LV function (LV ejection fraction) and
filling pressure parameters were normal and similar in the two
groups at baseline and discharge (Table 2). Median NT-proBNP
concentration was moderately and similarly increased from
Table 3. Baseline morphological and functional valvular abnormalities.
Benfluorex (n=310) Pioglitazone (n=305) All (n=615)
Morphological abnormalities n=309 n=305 n=614
At least one abnormality on any valve 154 (50%) 160 (53%) 314 (51%)
Aortic valve n=306 n=302 n=608
At least one abnormality 101 (33%) 100 (33%) 201 (33%)
Thickness 95 (31%) 94 (31%) 189 (31%)
Calcification 33 (11%) 25 (8%) 58 (10%)
Mitral valve n=307 n=300 n=607
At least one abnormality 125 (41%) 127 (42%) 252 (42%)
Thickness 114 (37%) 120 (40%) 234 (39%)
Calcification 26 (9%) 20 (7%) 46 (8%)
Tricuspid valve n=302 n=300 n=602
At least one abnormality 10 (3%) 11 (4%) 21 (4%)
Thickness 10 (3%) 11 (4%) 21 (4%)
Calcification – – –
Functional abnormalities n=309 n=303 n=612
At least one abnormality on any valve 260 (84%) 255 (84%) 515 (84%)
Aortic valve n=309 n=302 611
At least one abnormality 53 (17%) 48 (16%) 101 (17%)
Regurgitation grade 1 49 (16%) 42 (14%) 91 (15%)
grade 2 – 4 (1%) 4 (0.7%)
Stenosis 7 (2%) 4 (1%) 11 (2%)
Mitral valve n=309 n=300 n=609
At least one abnormality 191 (62%) 180 (60%) 371 (61%)
Regurgitation Grade 1 186 (60%) 175 (58%) 361 (59%)
Grade 2 3 (1%) 5 (2%) 8 (1%)
Grade 3 1 (0.3%) – 1 (0.2%)
Stenosis 1 (0.3%) 2 (0.7%) 3 (0.5%)
Tricuspid valve n=304 n=299 n=603
At least one abnormality 208 (68%) 228 (76%) 436 (72%)
Regurgitation Grade 1 208 (68%) 225 (75%) 433 (72%)
Grade 2 – 3 (1%) 3 (0.5%)
Stenosis – – –
Values are numbers (%). n=number of assessable patients.
doi:10.1371/journal.pone.0038273.t003
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Emergent valvular abnormality
Change in grade from
baseline to last value
Benfluorex
(n=310)
Pioglitazone
(n=305) p value
Odds Ratio
(95%CI)
Aortic regurgitation n=309 n=302
Total 42 (14%) 3 (1%) p,0.0001 15.52 [4.76;50.66]
Grade 0 to 1 40 (13%) 3 (1%)
Grade 0 to 2 1 (0.3%) –
Grade 1 to 2 1 (0.3%) –
Mitral regurgitation n=309 n=300
Total 22 (7%) 14 (5%) p=0.19 1.58 [0.79;3.16]
Grade 0 to 1 21 (7%) 13 (4%)
Grade 1 to 2 1 (0.3%) 1 (0.3%)
Tricuspid regurgitation n=304 n=299
Total 33 (11%) 17 (6%) p=0.024 2.01 [1.10;3.70]
Grade 0 to 1 33 (11%) 15 (5%)
Grade 1 to 2 – 2 (0.7%)
At least two valvular emergent
regurgitations
16 (5%) 1 (0.3%) P=0.007 16.43 [2.124]
3 valvular emergent regurgitations 4 (1%) –
Values are numbers (%). n=number of assessable patients.
doi:10.1371/journal.pone.0038273.t004
Figure 3. Example of an emergent grade 1 aortic regurgitation in a patient treated with benfluorex. In the parasternal views (row A) and
the apical 3-chamber views (row B), grade 1 aortic regurgitation is shown by colour Doppler (arrow) after 1 year of treatment with benfluorex.
doi:10.1371/journal.pone.0038273.g003
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benfluorex and from 49.0 to 70.0 pg/mL with pioglitazone. Since
the tricuspid regurgitation trace was often inadequate for peak
velocity quantification, systolic pulmonary arterial pressure was
evaluable in only 68 patients, and no clinically relevant change was
detected. Systolic pulmonary arterial pressure above 40 mm Hg
after baseline was detected in 4/30 patients with benfluorex and
9/38 patients with pioglitazone.
About half of the patients had at least one morphological
valvular abnormality at baseline, mainly mild thickening, while
84% had at least one functional abnormality in any valve, mostly
grade 1 regurgitation (Table 3). Mild aortic valve stenosis was
found in 11 (2%) patients and mitral stenosis in 3 (0.5%) patients.
The prevalence was similar in the two groups.
During the study, 12 (2%) patients had emergent morphological
abnormalities (8 patients [3%] with benfluorex, 4 [1%] patients
with pioglitazone) (OR 1.99, 95% CI 0.59–6.69, p=0.26).
Emergent regurgitation (new or increased by at least one grade)
occurred more frequently with benfluorex (82 [27%] patients) than
with pioglitazone (33 [11%] patients) (OR 2.97, 95% CI 1.91–
4.63, p,0.0001) (Table 4). Regurgitations more frequently
involved the aortic valve (42 [14%] patients with benfluorex, 3
[1%] patients with pioglitazone) (OR 15.52, 95% CI 4.76–50.66,
p,0.0001) (Figure 3) than the mitral valve (21 [7%] patients with
benfluorex, 14 [5%] patients with pioglitazone) (OR 1.58, 95% CI
0.79–3.16, p=0.19) or the tricuspid valve (33 [11%] patients with
benfluorex, 17 [6%] patients with pioglitazone) (OR 2.01, 95% CI
1.10–3.70, p=0.024). Most of these emergent regurgitations were
rated as grade 1 (81 [27%] patients with benfluorex, 30 [10%]
patients with pioglitazone) (OR 3.25, 95% CI 2.06–5.13,
p,0.0001). Emergent regurgitation graded 2 was detected in 2
(0.7%) patients with benfluorex and 3 (1%) patients with
pioglitazone (p=0.64). No moderate or severe regurgitation and
no valvular stenosis occurred during the study.
These emergent valvular abnormalities were not associated with
any clinical signs. In benfluorex group, NT-proBNP median level
reached 70.5 pg/mL in patients with emergent regurgitation and
73.0 pg/mL in patients without emergent regurgitation.
Multivariable analysis identified the following predictors for
emergent valvular regurgitation in the overall population: systemic
hypertension at baseline (OR 0.58, 95% CI 0.37–0.90), female
gender (OR 1.61, 95% CI 1.04–2.48), morphological abnormal-
ities at baseline (OR 1.78, 95% CI 1.14–2.78), and treatment with
benfluorex (OR 3.20, 95% CI 2.03–5.05). When considering only
Table 5. Emergent adverse events leading to treatment withdrawal (in more than one patient in any group) by system organ class
and preferred terms in the safety set (N=844).
System organ class Benfluorex (n=421) Pioglitazone (n=423)
No of
events
No (%) of
patients
No of
events
No (%) of
patients
All 43 40 (10%) 37 35 (8%)
Cardiac disorders 7 7 (2%) 7 7 (2%)
Cardiac failure 2 2 (0.5%) 3 3 (0.7%)
Myocardial infarction 2 2 (0.5%) 2 2 (0.5%)
Gastrointestinal disorders 11 9 (2%) 2 2 (0.5%)
Diarrhoea 3 3 (0.7%) – –
Gastrointestinal disorder 2 2 (0.5%) – –
Nervous system disorders 5 5 (1%) 3 3 (0.7%)
General disorders and administration site conditions 2 2 (0.5%) 5 5 (1%)
Oedema – – 3 3 (0.7%)
Asthenia 2 2 (0.5%) – –
Oedema peripheral – – 2 2 (0.5%)
Investigations 2 2 (0.5%) 4 4 (0.9%)
Weight increase – – 3 3 (0.7%)
Hepatic enzyme increase 2 2 (0.5%) – –
Neoplasms benign, malignant and unspecified (including cysts and
polyps)
3 3 (0.7%) 2 2 (0.5%)
Blood and lymphatic system disorders 2 2 (0.5%) 2 2 (0.5%)
Anaemia 2 2 (0.5%) 2 2 (0.5%)
Infections and infestations 3 3 (0.7%) 1 1 (0.2%)
Respiratory, thoracic, and mediastinal disorders 1 1 (0.2%) 2 2 (0.5%)
Injury, poisoning, and procedural complications 2 2 (0.5%) – –
Fall 2 2 (0.5%) – –
Metabolism and nutrition disorders – – 2 2 (0.5%)
Musculoskeletal and connective tissue disorders 2 2 (0.5%) – –
Pregnancy, puerperium and perinatal conditions – – 2 2 (0.5%)
Pregnancy – – 2 2 (0.5%)
doi:10.1371/journal.pone.0038273.t005
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morphological abnormalities at baseline (OR 2.23, 95% CI
1.28–3.88) and female gender (OR 1.83, 95% CI 1.06–3.16),
whereas none were found significant in the pioglitazone group,
likely due to the low number of emergent regurgitations.
Six patients died during the trial: 2 in benfluorex group
(metastatic neoplasm, and acute renal failure subsequent to
surgery for metastatic ovarian cancer) and 4 in pioglitazone group
(road traffic accident, plasmacytoma, aspergillosis, and myocardial
infarction). None of the deaths was considered as treatment-related
according to the investigators or Adjudication Committee.
Emergent adverse events leading to treatment interruption are
listed in Table 5. The total number of patients with at least one
serious adverse event was 32 in benfluorex group and 37 in
pioglitazone group. Emergent suspected hypoglycaemia affected
less frequently benfluorex (38 [9%]) than pioglitazone (56 [13%])
patients (p=0.052).
Discussion
REGULATE shows that benfluorex was less effective at
reducing HbA1c than pioglitazone and was responsible for an
increase in valvular regurgitation with an estimated odds ratio of
nearly 3. Of note, our study planned an echocardiographic follow-
up and aimed to take into account all degrees of valvular
regurgitation, including grade 1 cases. This is the largest
prospective controlled study to assess the development of cardiac
valvular abnormalities with benfluorex, and therefore supports a
causal relationship. The echocardiography study was designed to
evaluate changes in valvular regurgitation with time. Side-by-side
assessment of echocardiograms eliminated potential bias due
temporal variability or drift, as reported in serial echocardiogra-
phy observations [13].In this population of diabetic patients with a
high prevalence of baseline minor valvular abnormalities, we
observed a significant increase in the incidence of valvular
regurgitation with benfluorex (82) versus pioglitazone (33) (OR
2.97, 95% CI (1.91 to 4.63), p,0.0001). These regurgitations were
mainly grade 1 and located on the aortic valve. None of them was
associated with any clinical symptoms or adverse events. Most
affected the aortic valve and cannot be related to volume overload.
Moreover, in pioglitazone group, despite a significant weight gain
partly related to hypervolemia, there was a smaller increase in
mitral and aortic regurgitation, though a protection of pioglitazone
against endocardial alteration seems unlikely. There was no
significant change in valvular morphology between the two
groups. As we identified valvular thickening at baseline in more
than 50% of patients and did not quantify the increase in
thickness, we failed to observe any significant morphologic
changes. In addition, the assessment of valvular thickening may
vary with the machine-settings however the randomized design of
our trial should avoid any systematic bias. We did not observe any
restrictive valvular motion as previously described by Van Camp
et al in pergolide induced valvulopathy [14].
Drug-induced valvular heart disease is characterised by diffuse
collections of thick white plaques composed of myofibroblasts.
These plaques are deposited on the endocardial surfaces.
Echocardiography usually shows thickening of both valve leaflets
and the subvalvular apparatus. In the mitral valve, thickening and
shortening of chordae tendinae cause tethering of the posterior
leaflet responsible for mal-coaptation of leaflets and valvular
regurgitation.
This detrimental effect of benfluorex occurred despite a
relatively short-term exposure (about 1 year), but at higher
cumulative doses (mean 151.5 g) than those recently reported to
be responsible for severe regurgitation [9].Indeed, a retrospective
analysis of a cohort of 1 million diabetic patients (4% treated with
benfluorex) reported a dose-effect relationship, with a relative risk
of hospitalisation of 2.9 (95% CI 2.2–3.7) [9]. Patients with lower
cumulative doses (,40.5 g) were less likely to be hospitalised for
valvular insufficiency. In our study, despite the high cumulative
dose, no severe valvular regurgitation was observed over 1 year’s
exposure. Our findings regarding the emergence of valvular
regurgitation were consistent in term of odds ratio with the relative
risk of hospitalisation for valvular disease reported in this
retrospective study [9].
Long treatment duration and high doses of fenfluramine have
been shown as predictors of fibrotic valvular regurgitation [15].
The prevalence of valvular abnormalities increased in patients
treated with fenfluramine/phentermine versus controls, after only
6 months’ exposure and mainly resulted in mild grades of aortic
regurgitation [15,16]. Similar results were found in patients
treated with dexfenfluramine [13]. From case-control reports,
evidence exists for severe mitral regurgitation requiring surgery
[8].
Benfluorex, a fenfluramine derivative, was prescribed in type 2
diabetes patients but was often misused as an appetite suppressant.
Norfenfluramine is one of the active metabolites of benfluorex [4],
and may be involved in the development of valvular heart disease
in exposed patients through an agonist effect on the 5-HT2B
receptors. The role of 5-hydroxytryptamine (5-HT), its transporter
(5-HTT), and 5-HT2B receptors has been established in various
pathological and experimental studies[17–21]. Reduced 5-HT
inactivation and therefore increased bioavailability of 5-HT was
the first proposed mechanism for the valvular heart disease
observed in individuals treated with fenfluramine/phentermine
[20]. A key role for 5-HTT expressed by cardiac and lung tissues,
was proposed through a modulation of systemic availability of 5-
HT [22]. Indeed, this protein is responsible for 5-HT uptake and
subsequent inactivation of 5-HT passing through the lung [22].
This may explain why patients exposed to appetite suppressants
develop mainly left-sided valvular abnormalities, whereas carci-
noid valve alterations are located mostly on the right side.
Among the serotonergic receptor subtypes, the 5-HT2B receptor
was identified as the mitogenic receptor that would be activated by
all the valvulopathic drugs, such as fenfluramine, methysergide,
ergotamine, pergolide, and cabergoline [23–27]. Previous studies
in mice lacking or overexpressing 5-HT2B receptors also revealed
important roles for this receptor in heart morphogenesis and
cardiomyocyte hypertrophy [28]. Additionally, cyproheptadine, a
5-HT2B receptor antagonist, was shown to prevent toxic valvulo-
pathy in a rat model of pergolide-induced valvular heart disease
[23]. However, as underlined by Rothman et al [19], if activation
of 5-HT2B receptors is necessary to produce valvular heart disease,
other factors such as 5-HTT expression [29], hypoxia, inflamma-
tory cytokines, and drugs, might also determine the individual
susceptibility to develop the lesion, its anatomic location and its
severity [17]. This might explain why a limited subset of patients
may progress to severe valvular damage, sometimes in short period
of times. Our study failed to identify a group at higher risk for
valvular abnormalities since multivariable analysis did not detect
any clinical or biological parameter indicating a higher risk profile
except for previous valvular abnormalities and gender.
Benfluorex was withdrawn from the market in 2009 with the
contribution of the REGULATE trial results, which provided
evidence for a causal relationship between exposure to benfluorex
and valvular alterations. The French Medicine drug agency
(AFSSAPS) recommends echocardiography in patients who
received benfluorex.
Valvular Toxicity of Benfluorex
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regression or latent development of valvular regurgitation will
occur after drug withdrawal. A prospective survey is ongoing to
explore this issue in the French population exposed to benfluorex.
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